Long-term follow-up of chronic hepatitis C patients treated with oral lactoferrin for 12 months
- Hepatol Res 2003 Mar;25(3):226-233
Long-term follow-up of chronic hepatitis C patients treated with oral
lactoferrin for 12 months.
Ishii K, Takamura N, Shinohara M, Wakui N, Shin H, Sumino Y, Ohmoto
Y, Teraguchi S, Yamauchi K.
Second Department of Internal Medicine, Toho University School of
Medicine, 6-11-1, Omori-nishi, Ota-ku, 143, Tokyo, Japan
BACKGROUND/AIMS: Bovine lactoferrin (bLF) has been shown to prevent
the infection of cultured hepatocytes by hepatitis C virus (HCV). The
present study attempted to clarify the effects of long-term
administration of bLF on serum parameters, including immunomodulatory
cytokines, in patients with chronic hepatitis C (CHC). METHODS:
Sixty-three CHC patients were randomly assigned into 2 groups. At an
oral dose of 600 mg/day, bLF was administered for 12 months to 36
patients (bLF group), while no bLF was given to the remaining 27
patients (control group. Serum levels of alanine aminotransferase,
HCV-RNA, IL-10, and IL-18 were evaluated, as well as CD4-positive T
cell subsets in the peripheral blood. RESULTS: The serum IL-18 level
was increased by bLF administration, but not in the control group.
After 3 months of bLF treatment, it was significantly higher than
before bLF administration, but it decreased gradually thereafter. The
percentage of interferon (IFN)-gamma+ and IL-4- (Th1) cells in the
peripheral blood increased along with the serum IL-18 level, although
the change was not statistically significant. The other parameters
did not change significantly during the study period in both groups.
CONCLUSIONS: These results suggest that oral administration of bLF to
CHC patients for up to 3 months can produce a Th1-cytokine dominant
environment in the peripheral blood that favors the eradication of
HCV by IFN therapy.
PMID: 12697243 [PubMed - as supplied by publisher]
Do you Yahoo!?
The New Yahoo! Search - Faster. Easier. Bingo